GAITHERSBURG, Md., April 12, 2017 -- OpGen, Inc. (NASDAQ:OPGN) today announced that five posters featuring its technologies will be presented at the 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 22-25, 2017 in Vienna, Austria. Among them will be a poster presentation titled “Prediction of antibiotic resistance in Escherichia Coli from resistance genes” by Dr. Terry Walker, Senior Vice President of Research and Development at OpGen. The presentation will highlight preliminary results supporting OpGen’s efforts to develop and commercialize a rapid and highly accurate test that predicts antibiotic resistance using resistance gene detection and the bioinformatics capabilities of the Acuitas Lighthouse® Knowledgebase. The OpGen booth location is 32B.
The details for the presentations at ECCMID are as follows:
Poster title: Prediction of antibiotic resistance in Escherichia coli from resistance genes
Presenter: T. Walker, OpGen
Date and time: Tuesday, April 25 from 12:54 - 12:59 pm CEST
Location: Poster Area
Poster number: #EP0938
Abstract number: #4182
Session info: Direct detection methods
Poster title: Use of the Acuitas Resistome Test to detect and type carbapenemase producing organisms (CPOs): A pilot study
Presenter: G. Vanstone, Royal Free London NHS Foundation Trust
Date and time: Saturday, April 22 from 3:30 - 4:30 pm CEST
Location: Poster Area
Poster number: #P0387
Abstract number: #6205
Session info: Detection of resistant pathogens
Poster title: Rapid outbreak detection of multi-drug resistant organisms using resistance genes profiles
Presenter: W. Chang, OpGen
Date and time: Saturday, April 22 from 8:45 am - 3:30 pm CEST
Location: Poster Area
Poster number: #EV0483
Abstract number: #5396
Session info: Resistance surveillance & epidemiology: Gram-negatives
Poster title: Evaluation of QuickFISH and the Sepsityper assays for early identification of aetiological agents in bloodstream infection in a clinical routine setting
Presenter: A. Pernestig, Systems Biology Research Centre, University of Skövde
Date and time: Monday, April 24 from 1:30 - 2:30 pm CEST
Location: Poster Area
Poster number: #P1561
Abstract number: #1166
Session info: Diagnostic microbiology
Poster title: Seven years of clinical experience with the Yeast Traffic Light PNA FISH: assay performance and implications on antifungal therapy
Presenter: V. Özenci, Karolinska University Hospital
Date and time: Sunday, April 23 from 1:30 - 2:30 pm CEST
Location: Poster Area
Poster number: #P0969
Abstract number: #5533
Session info: Diagnostic mycology I
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
OpGen Contact: Michael Farmer Director, Marketing 240-813-1284 [email protected] [email protected] OpGen Investor and Media Contact: MacDougall Biomedical Communications Cammy Duong 781-591-3443 [email protected]


Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Washington Post Publisher Will Lewis Steps Down After Layoffs
Anta Sports Expands Global Footprint With Strategic Puma Stake
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 



